The cause of MSA remains unknown. Several lines of evidence suggest that inflammation could contribute to neurodegeneration in MSA. [9–11] Microglia are the primary immune effector cells in the brain.

Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease. The Phase 2a study (ClinicalTrials.gov ...

Multiple System Atrophy is a rare and debilitating disorder involving the progressive loss of nerve cells in several areas of the brain. Symptoms may include severe problems with movement, balance, ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...

Orthostatic hypotension is a cardinal feature of multiple-system atrophy. The upright posture provokes syncopal episodes that prevent patients from standing and walking for more than brief periods. We ...

Emerging evidence suggests widely used metabolic drugs could influence brain aging pathways, yet large clinical trials are still needed to confirm whether they truly alter the course of ...

Biohaven Pharmaceutical BHVN announced that its pipeline candidate, verdiperstat failed to meet the primary and secondary endpoints of the phase III study evaluating it in patients with multiple ...

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...